SML2322
Ilaprazole
≥98% (HPLC)
Synonym(s):
2-[[(4-Methoxy-3-methyl-2-pyridinyl)methyl]sulfinyl]-6-(1H-pyrrol-1-yl)-1H-benzimidazole, IY 81149, IY-81149
Sign Into View Organizational & Contract Pricing
Select a Size
About This Item
Empirical Formula (Hill Notation):
C19H18N4O2S
CAS Number:
Molecular Weight:
366.44
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77
Assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
−20°C
SMILES string
[S](=O)(Cc4nccc(c4C)OC)c1[nH]c2c(n1)cc(cc2)[n]3cccc3
InChI
1S/C19H18N4O2S/c1-13-17(20-8-7-18(13)25-2)12-26(24)19-21-15-6-5-14(11-16(15)22-19)23-9-3-4-10-23/h3-11H,12H2,1-2H3,(H,21,22)
InChI key
HRRXCXABAPSOCP-UHFFFAOYSA-N
Related Categories
Biochem/physiol Actions
Ilaprazole is a proton pump inhibitor (H+/K+ ATPase inhibitor) that suppresses acids secretion. Ilaprazole is a potent and selective inhibitor of T-cell-originated protein kinase (TOPK) that suppresses cancer growth.
proton pump inhibitor (H+/K+ ATPase inhibitor)
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
D Kwon et al.
Arzneimittel-Forschung, 51(3), 204-213 (2001-04-18)
The inhibitory effects of IY-81149 (2-[[(4-methoxy-3-methyl)-2- pyridinyl]methyl-sulfinyl]-5-(1H-pyrol-1-yl)-1H-benzimidazole, CAS 172152-36-2), a newly developed proton pump inhibitor (PPI) on gastric acid secretion were investigated in vitro and in vivo. In rabbit parietal cell preparation, IY-81149 irreversibly inhibited H+/K(+)-ATPase in dose-dependent manner with
Mengzhu Zheng et al.
Oncotarget, 8(24), 39143-39153 (2017-04-08)
T-cell-originated protein kinase (TOPK) is highly and frequently expressed in various cancer tissues and plays an indispensable role in the mitosis of cancer cells, and therefore, it is an important target for drug treatment of tumor. Ilaprazole was identified to
J S Shin et al.
Alimentary pharmacology & therapeutics, 40(5), 548-561 (2014-07-22)
Ilaprazole, a proton pump inhibitor (PPI) currently in clinical use, may provide improved acid suppression vs. other PPIs. To compare the pharmacodynamic and pharmacokinetic profiles of ilaprazole and esomeprazole. A phase 1, randomised, open-label, single-centre, 4-period crossover study was conducted
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service